Formulation and Development OF BCS Class II Drug

The aim of this research was to develop and evaluate liquisolid compacts of Voriconazole a BCS class II drug. The series of formulations containing Voriconazole drug were formulated by using aerosil a colloidal silicone dioxide and avicel PH microcrystalline cellulose in different ratios by using suitable solvent. Solubility studies were performed in propylene glycol and polyethylene glycol (PEG-200, 400, 600) for the choice of the best non volatile liquid to dissolve Voriconazole. On the basis of the solubility data PEG 600 was chosen as a good solvent for the Voriconazole. Voriconazole was dissolved in solvent PEG 600 for the preparation of solution of drug. Formulated compacts were evaluated for all post compression parameters and the in-vitro drug release study was carried out. All the formulations have shown a very good drug release in  15 min except compressibility problems due to higher loading factor of liquid vehicle for the formulations. The selected formulation FV10 containing 30% of drug solution has  shown good drug release of 100.2.% in 15  min compared to dissolution of  pure drug and marketed tablet which shown 58.5.5%  and 70..6 % respectively.No interactions were found  between drug and polymers in FITR as well as DSC. XRD of selected formulation shows that drug present in the formulation is in amorphous form. Keywords: Voriconazole HCl, Avicel PH, Aerosil 200, Poly-Ethylene Glycol 600, liquisolid compacts

Formulation and evaluation of transdermal drug delivery system of verapamil hydrochloride

The aim of this research was to develop and evaluate a matrix type of transdermal drug delivery system containing Verapamil Hydrochloride. The series of formulations containing Verapamil Hydrochloride were formulated by using different polymers like HPMC (hydrophilic), CAP (hydrophobic) and EC (hydrophobic) in different ratios by solvent evaporation technique. Propylene glycol and Dibutyl phthalate were used as plasticizers. The 20% and 40% of DMSO is used as the penetration enhancer. Formulated transdermal patches were physically evaluated for thickness, weight variation, drug content, flatness, tensile strength, folding endurance, and water vapour transmission rate. The in-vitro drug release study was carried out by using Franz diffusion cell. The data obtained from release study shows increased percentage of drug permeated in 20% of DMSO containing formulation than 40% of DMSO containing formulation. Drug permeation is enhanced in the formulation containing high concentration of HPMC (VH1). The VH2 and VH6 helped in maintaining the rate of release at a constant level (20% DMSO). But in case of 40% DMSO is used as the concentration of CAP increases the rate of permeation increases. Skin irritation study does not show any irritation on the skin of rabbit. There is no possible interaction between drug and polymers in FITR as well as DSC. XRD of selected formulation shows that drug present in the formulation is in crystalline form. Keywords: Verapamil HCl, HPMC, EC, CAP, DMSO, TDDS, Solvent evaporatio

BULLOUS PEMPHIGOID A RARE AUTOIMMUNE DISEASE: A CASE REPORT

Background. Bullous pemphigoid (BP) is a rare autoimmune blistering skin disease in the elderly and it is manifested by cutaneous blisters on the skin lesions. The objective was to emphasize the rare case of BP. Methods. A case report of BP in a 58-year-old male patient admitted to a dermatology ward is presented. Results. A 58-year-old male patient with complaints of fluid-filled skin lesions, was examined initially over the trunk, gradually progressed involving B/L upper and lower extremities. Even though the patient was treated with the recommended therapy of corticosteroid (Dexamethasone) along with adjuvant drugs, new skin lesions continued to develop, and the patient’s condition worsened. The Prednisolone was started in place of Dexamethasone on the fifth day of treatment at its higher dose (50mg/day), the Prednisolone proved its efficacy to combat the extensive condition of BP. Conclusions. Bullous pemphigoid is a distressing blistering skin disease. Untreated disease is often fatal because of the susceptibility to infection and fluid-electrolyte disturbances. The mortality of patients with bullous pemphigoid has been significantly reduced with the advent of new therapies and treatment modalities. The treatment with systemic and topical corticosteroids forms the mainstay of treatment along with other adjuvant drugs. In the present case study, the use of Prednisolone has proven its efficacy in the extensive disease state of BP and improved the patient’s quality of life